It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Bacteria adapt to selective pressure in their immediate environment in multiple ways. One mechanism involves the acquisition of independent mutations that disable or modify a key pathway, providing a signature of adaptation via convergent evolution. Extra-intestinal pathogenic Escherichia coli (ExPEC) belonging to sequence type 95 (ST95) represent a global clone frequently associated with severe human infections including acute pyelonephritis, sepsis, and neonatal meningitis. Here, we analysed a publicly available dataset of 613 ST95 genomes and identified a series of loss-of-function mutations that disrupt cellulose production or its modification in 55.3% of strains. We show the inability to produce cellulose significantly enhances ST95 invasive infection in a rat model of neonatal meningitis, leading to the disruption of intestinal barrier integrity in newborn pups and enhanced dissemination to the liver, spleen and brain. Consistent with these observations, disruption of cellulose production in ST95 augmented innate immune signalling and tissue neutrophil infiltration in a mouse model of urinary tract infection. Mutations that disrupt cellulose production were also identified in other virulent ExPEC STs, Shigella and Salmonella, suggesting a correlative association with many Enterobacteriaceae that cause severe human infection. Together, our findings provide an explanation for the emergence of hypervirulent Enterobacteriaceae clones.
Extra-intestinal pathogenic Escherichia coli cause urinary tract and bloodstream infections. Here, the authors show how mutations that disrupt the production of cellulose, a polysaccharide produced by many bacteria, drive enhanced virulence.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details













1 The University of Queensland, Institute for Molecular Bioscience (IMB), Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); The University of Queensland, School of Chemistry and Molecular Biosciences, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); The University of Queensland, Australian Infectious Diseases Research Centre, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
2 The University of Queensland, Australian Infectious Diseases Research Centre, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); The University of Queensland, Translational Research Institute, Immunopathology Group, Mater Research Institute, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); QIMR Berghofer Medical Research Institute, Brisbane QLD, Australia (GRID:grid.1049.c) (ISNI:0000 0001 2294 1395)
3 Griffith University, School of Pharmacy and Medical Sciences, Southport, Australia (GRID:grid.1022.1) (ISNI:0000 0004 0437 5432); Griffith University, Menzies Health Institute Queensland, Southport, Australia (GRID:grid.1022.1) (ISNI:0000 0004 0437 5432)
4 The University of Queensland, School of Biomedical Sciences, Faculty of Medicine, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); The University of Queensland, Queensland Brain Institute, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
5 The University of Queensland, School of Chemistry and Molecular Biosciences, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); The University of Queensland, Australian Infectious Diseases Research Centre, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); INRAE, Univ Montpellier, LBE, Narbonne, France (GRID:grid.419083.7) (ISNI:0000 0004 7648 3555)
6 The University of Queensland, School of Chemistry and Molecular Biosciences, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); The University of Queensland, Australian Infectious Diseases Research Centre, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); Queen’s University Belfast, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521)
7 The University of Queensland, School of Chemistry and Molecular Biosciences, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); The University of Queensland, Australian Infectious Diseases Research Centre, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); Royal Brisbane and Women’s Hospital, Central Microbiology, Pathology Queensland, Brisbane, Australia (GRID:grid.416100.2) (ISNI:0000 0001 0688 4634)
8 Griffith University, School of Pharmacy and Medical Sciences, Southport, Australia (GRID:grid.1022.1) (ISNI:0000 0004 0437 5432); Griffith University, Menzies Health Institute Queensland, Southport, Australia (GRID:grid.1022.1) (ISNI:0000 0004 0437 5432); University of East Anglia, School of Biological Sciences, Norwich, UK (GRID:grid.8273.e) (ISNI:0000 0001 1092 7967)
9 The University of Queensland, Australian Infectious Diseases Research Centre, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); The University of Queensland, Translational Research Institute, Immunopathology Group, Mater Research Institute, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
10 The University of Queensland, School of Chemistry and Molecular Biosciences, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); The University of Queensland, Australian Infectious Diseases Research Centre, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
11 The University of Queensland, Institute for Molecular Bioscience (IMB), Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); The University of Queensland, Australian Infectious Diseases Research Centre, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
12 The University of Queensland, Australian Infectious Diseases Research Centre, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); University of Queensland Centre for Clinical Research, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); Queensland Children’s Hospital, Brisbane, Australia (GRID:grid.240562.7)